ALDURAZYME® (laronidase) is indicated for the treatment of adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.
Limitations of Use:
- The safety and effectiveness of treating mildly affected patients with the Scheie form have not been established.
- The effect of ALDURAZYME on central nervous system manifestations of the disorder has not been determined.
6-MWT = six-minute walk test; FVC = forced vital capacity; MPS I = mucopolysaccharidosis type I.
Reference: 1. ALDURAZYME [prescribing information]. Cambridge, MA: Genzyme Corporation.